GeoVax, Allucent in Phase 2b for Next-Gen COVID Vax with BARDA Funding

 10,000-participant randomized Phase 2b study will evaluate and compare GeoVax's multi-antigen, vaccine candidate (GEO-CM04S1) to an approved vaccine against COVID-19

Study is Funded by BARDA through Project NextGen, executed through its Clinical Studies Network

https://finance.yahoo.com/news/geovax-partners-allucent-conduct-phase-130000560.html